John Catalano

John Catalano

UNVERIFIED PROFILE

Are you John Catalano?   Register this Author

Register author
John Catalano

John Catalano

Publications by authors named "John Catalano"

Are you John Catalano?   Register this Author

59Publications

2421Reads

24Profile Views

Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.

Leuk Lymphoma 2018 02 8;59(2):493-496. Epub 2017 Jun 8.

a Department of Clinical Haematology , Alfred Hospital , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1334122DOI Listing
February 2018

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

J Clin Oncol 2017 Dec 20;35(34):3844-3850. Epub 2017 Sep 20.

Ruben A. Mesa, Mayo Clinic Cancer Center, Scottsdale, AZ; Jean-Jacques Kiladjian, Saint-Louis Hospital (Assistance Publique-Hôpitaux de Paris) and Paris Diderot University, Paris, France; John V. Catalano, Frankston Hospital and Monash University, Melbourne, Victoria, Australia; Timothy Devos, University Hospital Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Miklos Egyed, Kaposi Mor Teaching Hospital, Kaposvar, Hungary; Andrzei Hellmann, Medical University of Gdańsk, Gdańsk, Poland; Donal McLornan, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom; Kazuya Shimoda, University of Miyazaki, Miyazaki, Japan; Elliott F. Winton, Emory University School of Medicine, Atlanta, GA; Wei Deng, Ronald L. Dubowy, and Julia D. Maltzman, Gilead Sciences, Foster City; Jason Gotlib, Stanford Cancer Institute, Stanford, CA; and Francisco Cervantes, Hospital Clinic, Institut D'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.4418
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.4418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553796PMC
December 2017

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

J Clin Oncol 2017 Aug 20;35(22):2473-2481. Epub 2017 Apr 20.

Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6984DOI Listing
August 2017

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.

Am J Hematol 2015 May 27;90(5):E86-91. Epub 2015 Feb 27.

Peter MacCallum Cancer Centre, East Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23967DOI Listing
May 2015

A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).

Br J Haematol 2014 Oct 11;167(2):243-51. Epub 2014 Jul 11.

Monash Medical Centre, Clayton, Vic., Australia; Australian Centre for Bloods Diseases, Monash University, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.13029
Publisher Site
http://dx.doi.org/10.1111/bjh.13029DOI Listing
October 2014

The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms.

Blood Coagul Fibrinolysis 2012 Jan;23(1):45-50

Clinical Immunohaematology Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MBC.0b013e32834d7ce3DOI Listing
January 2012

Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1.

Bioorg Med Chem Lett 2010 Apr 12;20(7):2186-90. Epub 2010 Feb 12.

Department of Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Research & Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.02.030DOI Listing
April 2010

Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1.

Bioorg Med Chem Lett 2009 Nov 19;19(22):6399-403. Epub 2009 Sep 19.

Department of Medicinal Chemistry, Metabolic and Virology Center of Excellence for Drug Discovery, GlaxoSmithKline Research & Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.09.056DOI Listing
November 2009

Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1.

Bioorg Med Chem Lett 2009 Sep 10;19(17):5048-52. Epub 2009 Jul 10.

Department of Medicinal Chemistry, Metabolic and Virology Center of Excellence for Drug Discovery, GlaxoSmithKline Research & Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.07.037DOI Listing
September 2009

Substituted tetrahydrocarbazoles with potent activity against human papillomaviruses.

Bioorg Med Chem Lett 2009 Jul 7;19(13):3489-92. Epub 2009 May 7.

Department of Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.05.003DOI Listing
July 2009

Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.

Bioorg Med Chem Lett 2007 Jan 17;17(1):22-7. Epub 2006 Nov 17.

Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2006.10.102DOI Listing
January 2007

Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.

Bioorg Med Chem Lett 2006 Mar 11;16(6):1735-9. Epub 2006 Jan 11.

Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.11.101DOI Listing
March 2006

Examining the potential exploitation of UNOS policies.

Am J Bioeth 2005 ;5(4):6-10

University of Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15265160590953085DOI Listing
December 2005

sacB-5-Fluoroorotic acid-pyrE-based bidirectional selection for integration of unmarked alleles into the chromosome of Rhodobacter capsulatus.

Appl Environ Microbiol 2005 Jun;71(6):3014-24

Johnson Research Foundation, Department of Biochemistry and Biophysics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AEM.71.6.3014-3024.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1151845PMC
June 2005

A structural screening approach to ketoamide-based inhibitors of cathepsin K.

Bioorg Med Chem Lett 2005 May;15(9):2209-13

Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.03.023DOI Listing
May 2005

NATCO, the organization for transplant professionals public policy statement. HIV-to-HIV transplantation.

Prog Transplant 2005 Mar;15(1):86-90

Center for Bioethic, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
March 2005

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.

Bioorg Med Chem Lett 2004 May;14(10):2543-6

Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2004.02.085DOI Listing
May 2004

Less Invasive Stabilization System for treatment of distal femur fractures.

Am J Orthop (Belle Mead NJ) 2004 May;33(5):250-5

Department of Orthopaedics, School of Osteopathic Medicine, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, USA.

View Article

Download full-text PDF

Source
May 2004

Design of small molecule ketoamide-based inhibitors of cathepsin K.

Bioorg Med Chem Lett 2004 Feb;14(3):719-22

Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2003.11.029DOI Listing
February 2004

Exploration of the P1 SAR of aldehyde cathepsin K inhibitors.

Bioorg Med Chem Lett 2004 Jan;14(1):275-8

Department of Medicinal Chemistry, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2003.09.088DOI Listing
January 2004